{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:57:11Z","timestamp":1790769431477,"version":"4.1.0"},"reference-count":44,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: This study aimed to investigate treatment patterns and survival outcomes in population-based data describing treatment and survival of primary vaginal carcinoma (VC) in a routine clinical setting, stratified by age group and stage.\nMethods: This nationwide, population-based study included women diagnosed with epithelial VC between 2011 and 2020, registered in the Swedish Quality Register for Gynecologic Cancer. Five-year relative survival (RS) was estimated using the Pohar Perme method. The excess mortality rate ratio (EMRR) was assessed by Poisson regression.\nResults: In total, 252 women were identified, 29% were aged \u2265 80 years. The median follow-up time was 7.5 years. The most common stages were I and II (26% each). Definitive radiotherapy, with or without chemotherapy, was administered to 59% of patients. Among women with stage I, 48% underwent primary surgery and 29% received adjuvant radiotherapy. Treatment patterns differed across age groups. Among women aged \u2265 80 years, staging was omitted in 18%, and in stage I disease 25% received palliative therapy. None of the irradiated women aged \u2265 80 years received chemoradiotherapy, compared to all women aged 20\u201359 years. The overall 5-year RS for stages I\u2013IV was 51% (95% confidence interval [CI] 43\u201358). In stages I\u2013II, the 5-year RS was 28% among women aged \u226580 years and 84% among those aged &lt; 60 years (EMRR of 5.2; 95% CI 1.7\u201315.6).\nInterpretation: Primary treatment of vaginal cancer in Sweden generally followed international guidelines, except among women aged \u2265 80 years. The markedly poorer RS in this age group suggests both diagnostic and therapeutic compromises.<\/jats:p>","DOI":"10.2340\/1651-226x.2026.45598","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:13:41Z","timestamp":1790766821000},"page":"805-813","source":"Crossref","is-referenced-by-count":0,"title":["Primary treatment and relative survival by stage and age in vaginal carcinoma: a population-based SweGCG study"],"prefix":"10.2340","volume":"65","author":[{"given":"Kristina","family":"Hellman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bjurberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Borgfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Dahm K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique","family":"Fl\u00f6ter R\u00e5destad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny-Maria","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preben","family":"Kj\u00f8lhede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Sk\u00f6ld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Stenstr\u00f6m Bohlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"St\u00e5lberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"\u00c5vall Lundqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"169724","doi-asserted-by":"crossref","unstructured":"Adams TS, Rogers LJ, Cuello MA. Cancer of the vagina: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl. 1):19\u201327.","DOI":"10.1002\/ijgo.13867"},{"key":"169725","unstructured":"Nordcan. Cancer Statistics for the Nordic countries (Nordcan) [Internet]. Available from: https:\/\/gco.iarc.fr\/media\/nordcan\/factsheets\/95\/en\/countries\/0\/vagina-228-nordcan_countries-0.pdf"},{"key":"169726","doi-asserted-by":"crossref","unstructured":"Forner DM. Characteristics and survival of primary vaginal malignancy: an analysis of the German nationwide cancer registry data. J Cancer Res Clin Oncol. 2023;149(3):1115\u201322.","DOI":"10.1007\/s00432-022-03982-7"},{"key":"169727","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN [Internet]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vaginal.pdf"},{"key":"169728","doi-asserted-by":"crossref","unstructured":"Nout R, Calaminus G, Planchamp F, Chargari C, Lax SF, Martelli H, et al. ESTRO\/ESGO\/SIOPe guidelines for the management of women with vaginal cancer. Radiother Oncol. 2023;186:109662.","DOI":"10.1016\/j.radonc.2023.109662"},{"key":"169729","unstructured":"RCC NVPcx\/vag. Regional Cancer Centre in Sweden (RCC). [Internet]. Available from: https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/livmoderhals-och-vaginalcancer\/vardprogram\/"},{"key":"169730","doi-asserted-by":"crossref","unstructured":"Guerri S, Perrone AM, Buwenge M, Ferioli M, Macchia G, Tagliaferri L, et al. Definitive radiotherapy in invasive vaginal carcinoma: a systematic review. Oncologist. 2019;24(1):132\u201341.","DOI":"10.1634\/theoncologist.2017-0546"},{"key":"169731","doi-asserted-by":"crossref","unstructured":"Jhingran A. Updates in the treatment of vaginal cancer. Int J Gynecol Cancer. 2022;32(3):344\u201351.","DOI":"10.1136\/ijgc-2021-002517"},{"key":"169732","doi-asserted-by":"crossref","unstructured":"Yang J, Delara R, Magrina J, Magtibay P, Langstraat C, Dinh T, et al. Management and outcomes of primary vaginal cancer. Gynecol Oncol. 2020;159(2):456\u201363.","DOI":"10.1016\/j.ygyno.2020.08.036"},{"key":"169733","doi-asserted-by":"crossref","unstructured":"Zhou WL, Yue YY. Radiotherapy plus chemotherapy is associated with improved survival compared to radiotherapy alone in women with primary vaginal carcinoma: a retrospective SEER study. Front Oncol. 2020;10:570933.","DOI":"10.3389\/fonc.2020.570933"},{"key":"169734","doi-asserted-by":"crossref","unstructured":"Rajagopalan MS, Xu KM, Lin JF, Sukumvanich P, Krivak TC, Beriwal S. Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base [NCDB] study. Gynecol Oncol. 2014;135(3):495\u2013502.","DOI":"10.1016\/j.ygyno.2014.09.018"},{"key":"169735","doi-asserted-by":"crossref","unstructured":"Sant M, Chirlaque Lopez MD, Agresti R, S\u00e1nchez P\u00e9rez MJ, Holleczek B, Bielska-Lasota M, et al. EUROCARE-5 Working Group: survival of women with cancers of breast and genital organs in Europe 1999\u20132007: results of the EUROCARE-5 study. Eur J Cancer. 2015;51(15):2191\u2013205.","DOI":"10.1016\/j.ejca.2015.07.022"},{"key":"169736","doi-asserted-by":"crossref","unstructured":"Tr\u00e9tarre B, Dantony E, Coureau G, Defossez G, Guizard AV, Delafosse P, et al. Trends in incidence of invasive vaginal cancer in France from 1990 to 2018 and survival of recently diagnosed women \u2013 a population-based study. Eur J Obstet Gynecol Reprod Biol. 2023;283:125\u20139.","DOI":"10.1016\/j.ejogrb.2023.02.003"},{"key":"169737","doi-asserted-by":"crossref","unstructured":"Huang J, Cai M, Zhu Z. Survival and prognostic factors in primary vaginal cancer: an analysis of 2004\u20132014 SEER data. Transl Cancer Res. 2020;9(11):7091\u2013102.","DOI":"10.21037\/tcr-20-1825"},{"key":"169738","unstructured":"Wilkinson EJ, Teixeira MR. Tumors of the vulva: epithelial tumors. In: Tavasolli FA, Devilee P, editors. World Health Organization classification of tumors. Pathology and genetics and tumors of the breast and female genital organs. Lyon: IARC Press; 2003. p. 316\u201325."},{"key":"169739","doi-asserted-by":"crossref","unstructured":"Hacker NF, Eifel PJ, van der Velden J. Cancer of the vagina. Int J Gynaecol Obstet. 2012;119(Suppl. 2):S97\u20139.","DOI":"10.1016\/S0020-7292(12)60022-8"},{"key":"169740","doi-asserted-by":"crossref","unstructured":"Barlow L, Westergren K, Holmberg L, Talb\u00e4ck M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27\u201333.","DOI":"10.1080\/02841860802247664"},{"key":"169741","doi-asserted-by":"crossref","unstructured":"Dahm-K\u00e4hler P, Borgfeldt C, Holmberg E, Staf C, Falconer H, Bjurberg M, et al. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin \u2013 on behalf of the Swedish Gynecological Cancer Group (SweGCG). Gynecol Oncol. 2017;144(1):167\u201373.","DOI":"10.1016\/j.ygyno.2016.10.039"},{"key":"169742","unstructured":"Gynekologisk cancer. \u00c5rsrapport Svenska Kvalitetsregistret f\u00f6r gynekologisk cancer (SQRGC) [Internet]. 2024. Available from: https:\/\/cancercentrum.se\/globalassets\/cancerdiagnoser\/gynekologi\/kvalitetsregister\/sqrgc_arsrapport_2023.pdf"},{"key":"169743","doi-asserted-by":"crossref","unstructured":"Bjurberg M, Hellman K, S\u00e4ll TA, Staf C, Borgfeldt C, Holmberg E, et al. Validation of data quality in the Swedish quality register of gynecologic cancer for cervical cancer and vulvar cancer \u2013 a Swedish Gynecologic Cancer Group (Swe-GCG) study. Acta Obstet Gynecol Scand. 2025;104(8):1530\u20138.","DOI":"10.1111\/aogs.15152"},{"key":"169744","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457\u201381.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"169745","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life\u2010tables. J R Stat Soc Series B. 1972;34(2):187\u2013220.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"169746","doi-asserted-by":"crossref","unstructured":"Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239\u201341.","DOI":"10.1093\/biomet\/69.1.239"},{"key":"169747","doi-asserted-by":"crossref","unstructured":"Pohar Perme M, Stare J, Est\u00e8ve J. On estimation in relative survival. Biometrics. 2012;68(1):113\u201320.","DOI":"10.1111\/j.1541-0420.2011.01640.x"},{"key":"169748","doi-asserted-by":"crossref","unstructured":"Clerc-Urm\u00e8s I, Grzebyk M, H\u00e9delin G. Net survival estimation with stns. Stata J. 2014;14(1):87\u2013102.","DOI":"10.1177\/1536867X1401400107"},{"key":"169749","doi-asserted-by":"crossref","unstructured":"Dickman PW, Coviello E. Estimating and modeling relative survival in Stata. Stata J. 2015;15(1):186\u2013215.","DOI":"10.1177\/1536867X1501500112"},{"key":"169750","unstructured":"Statistics Sweden [Internet]. Available from: www.scb.se"},{"key":"169751","doi-asserted-by":"crossref","unstructured":"Yagi A, Ueda Y, Kakuda M, Tanaka Y, Egawa-Takata T, Morimoto A, et al. Descriptive epidemiological study of vaginal cancer using data from the Osaka Japan population-based cancer registry: long-term analysis from a clinical viewpoint. Medicine (Baltimore). 2017;96(32):e7751.","DOI":"10.1097\/MD.0000000000007751"},{"key":"169752","doi-asserted-by":"crossref","unstructured":"Gunderson CC, Nugent EK, Yunker AC, Rocconi RP, Graybill WS, Erickson BK, et al. Vaginal cancer: the experience from 2 large academic centers during a 15-year period. J Low Genit Tract Dis. 2013;17(4):409\u201313.","DOI":"10.1097\/LGT.0b013e3182800ee2"},{"key":"169753","doi-asserted-by":"crossref","unstructured":"Stock RG, Chen AS, Seski J. A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol. 1995;56(1):45\u201352.","DOI":"10.1006\/gyno.1995.1008"},{"key":"169754","doi-asserted-by":"crossref","unstructured":"Otton GR, Nicklin JL, Dickie GJ, Niedetzky P, Tripcony L, Perrin LC, et al. Early-stage vaginal carcinoma \u2013 an analysis of 70 women. Int J Gynecol Cancer. 2004;14(2):304\u201310.","DOI":"10.1136\/ijgc-00009577-200403000-00017"},{"key":"169755","doi-asserted-by":"crossref","unstructured":"Hellman K, Lundell M, Silfversw\u00e4rd C, Nilsson B, Hellstr\u00f6m AC, Frankendal B. Clinical and histopathologic factors related to prognosis in primary squamous cell carcinoma of the vagina. Int J Gynecol Cancer. 2006;16(3):1201\u201311.","DOI":"10.1136\/ijgc-00009577-200605000-00039"},{"key":"169756","doi-asserted-by":"crossref","unstructured":"Yang J, Yin J, Yan G, Huang D, Wang J. Postoperative chemoradiotherapy versus radiotherapy alone for cervical cancer: a systematic review and meta-analysis. J Obstet Gynaecol. 2016;36(5):641\u20138.","DOI":"10.3109\/01443615.2015.1134458"},{"key":"169757","doi-asserted-by":"crossref","unstructured":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802\u201312.","DOI":"10.1200\/JCO.2008.16.4368"},{"key":"169758","doi-asserted-by":"crossref","unstructured":"Ghia AJ, Gonzalez VJ, Tward JD, Stroup AM, Pappas L, Gaffney DK. Primary vaginal cancer and chemoradiotherapy: a patterns-of-care analysis. Int J Gynecol Cancer. 2011;21(2):378\u201384.","DOI":"10.1097\/IGC.0b013e3182072e44"},{"key":"169759","doi-asserted-by":"crossref","unstructured":"Hanawa S, Mitsuhashi A, Usui H, Yamamoto N, Watanabe-Nemoto M, Nishikimi K, et al. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older. Int J Gynecol Cancer. 2015;25(5):891\u20136.","DOI":"10.1097\/IGC.0000000000000436"},{"key":"169760","doi-asserted-by":"crossref","unstructured":"Guler OC, Sari SY, Birgi SD, Gultekin M, Yildiz F, Onal C. Definitive chemoradiotherapy in elderly cervical cancer patients: a multiinstitutional analysis. Int J Gynecol Cancer. 2017;27(7):1446\u201354.","DOI":"10.1097\/IGC.0000000000001029"},{"key":"169761","doi-asserted-by":"crossref","unstructured":"Fiorentino A, De Bonis P, Chiesa S, Balducci M, Fusco V. Elderly patients with glioblastoma: the treatment challenge. Expert Rev Neurother. 2013;13(10):1099\u2013105.","DOI":"10.1586\/14737175.2013.840419"},{"key":"169762","unstructured":"Fiorica F, Stefanelli A, Pascale G, Fisichella R. Elderly gastrointestinal cancer patients and radiochemotherapy: a review. Clin Ter. 2014;165(1):57\u201361."},{"key":"169763","doi-asserted-by":"crossref","unstructured":"Candelaria M, Garcia-Arias A, Cetina L, Due\u00f1as-Gonzalez A. Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol. 2006;1:15.","DOI":"10.1186\/1748-717X-1-15"},{"key":"169764","doi-asserted-by":"crossref","unstructured":"Harada T, Sasaki T, Ishii H, Takemoto S, Hisamatsu Y, Saito H, et al. A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902). Thorac Cancer. 2024;15(29):2128\u201335.","DOI":"10.1111\/1759-7714.15444"},{"key":"169765","doi-asserted-by":"crossref","unstructured":"Bertoli HK, Baandrup L, Aalborg GL, Kjaer AK, Thomsen LT, Kjaer SK. Time trends in the incidence and survival of vaginal squamous cell carcinoma and high-grade vaginal intraepithelial neoplasia in Denmark \u2013 a nationwide population-based study. Gynecol Oncol. 2020;158(3):734\u20139.","DOI":"10.1016\/j.ygyno.2020.05.683"},{"key":"169766","doi-asserted-by":"crossref","unstructured":"Beller U, Benedet JL, Creasman WT, Ngan H, Quinn MA, Maisonneuve P, et al. Carcinoma of the Vagina. Int J Gynaecol Obstet. 2006;95(Suppl. 1):S29\u201342.","DOI":"10.1016\/S0020-7292(06)60029-5"},{"key":"169767","doi-asserted-by":"crossref","unstructured":"Loh KP, Liposits G, Arora SP, Neuendorff NR, Gomes F, Krok-Schoen JL, et al. Adequate assessment yields appropriate care-the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO\/SIOG Cancer in the Elderly Working Group. ESMO Open. 2024;9(8):103657.","DOI":"10.1016\/j.esmoop.2024.103657"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45598\/55671","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45598\/55671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:13:54Z","timestamp":1790766834000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/45598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":44,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2026.45598","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}